• ImmunityBio disclosed the issuance of five U.S. patents covering the combination of its IL-15 receptor agonist ANKTIVA (nogapendekin alfa inbakicept-pmln) with BCG for cancer treatment, with terms running through at least 2035.
• The patents cover the approved ANKTIVA-BCG product in non-muscle invasive bladder cancer, including intravesical dosing, a two-vial commercial kit, and related treatment methods.
• The company said the estate supports its commercial position in BCG-unresponsive NMIBC, a pending supplemental BLA for BCG-unresponsive papillary-only disease, and a registrational study in BCG-naive NMIBC carcinoma in situ.
• ImmunityBio also said the patents extend to combinations using any approved BCG strain, alongside its exclusive U.S. development and supply agreement for Tokyo-172 BCG.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260518605297) on May 18, 2026, and is solely responsible for the information contained therein.